Trial Profile
An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy in Patients With Advanced Stage, Asymptomatic, Non-Bulky Follicular Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms Watch and Wait
- 16 Aug 2023 This trial has been completed in Czech Republic.
- 09 May 2023 Planned End Date changed from 1 May 2022 to 1 May 2023.
- 17 Jun 2018 Long term results of the quality of life sub-study, presented at the 23rd Congress of the European Haematology Association.